[
    [
        {
            "time": "",
            "original_text": "复锐医疗科技(01696-HK)拟议股权变动",
            "features": {
                "keywords": [
                    "复锐医疗科技",
                    "股权变动",
                    "01696-HK"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复锐医疗科技(01696-HK)拟议股权变动",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "复星医药子公司拟3.9亿港元受让复锐医疗科技股权",
            "features": {
                "keywords": [
                    "复星医药",
                    "子公司",
                    "3.9亿港元",
                    "复锐医疗科技",
                    "股权受让"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药子公司拟3.9亿港元受让复锐医疗科技股权",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "专访复星医药董事长、复宏汉霖主席兼非执行董事陈启宇：单抗龙头复宏汉霖赴港上市 多款产品陆续进入商业化阶段",
            "features": {
                "keywords": [
                    "复星医药",
                    "陈启宇",
                    "复宏汉霖",
                    "赴港上市",
                    "单抗龙头",
                    "商业化阶段"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "专访复星医药董事长、复宏汉霖主席兼非执行董事陈启宇：单抗龙头复宏汉霖赴港上市 多款产品陆续进入商业化阶段",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]